Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment
Gregory G Schwartz, Michael Szarek, Vera A Bittner, Deepak L Bhatt, Rafael Diaz, Shaun G Goodman, J Wouter Jukema, Megan Loy, Garen Manvelian, Robert Pordy, Harvey D White, Philippe Gabriel Steg, ODYSSEY OUTCOMES Committees and Investigators
Abstract
Objective: In observational data, lower levels of lipoprotein(a) have been associated with greater prevalence of type 2 diabetes. Whether pharmacologic lowering of lipoprotein(a) influences incident type 2 diabetes is unknown. We determined the relationship of lipoprotein(a) concentration with incident type 2 diabetes and effects of treatment with alirocumab, a PCSK9 inhibitor.
Research design and methods: In the ODYSSEY OUTCOMES trial alirocumab was compared with placebo in patients with acute coronary syndrome. Incident diabetes was determined from laboratory, medication, and adverse event data.
Results: Among 13,480 patients without diabetes at baseline, 1,324 developed type 2 diabetes over a median 2.7 years. Median baseline lipoprotein(a) was 21.9 mg/dL. With placebo, 10 mg/dL lower baseline lipoprotein(a) was associated with hazard ratio 1.04 (95% CI 1.02-1.06, P < 0.001) for incident type 2 diabetes. Alirocumab reduced lipoprotein(a) by a median 23.2% with greater absolute reductions from higher baseline levels and no overall effect on incident type 2 diabetes (hazard ratio 0.95, 95% CI 0.85-1.05). At low baseline lipoprotein(a) levels, alirocumab tended to reduce incident type 2 diabetes, while at high baseline lipoprotein(a) alirocumab tended to increase incident type 2 diabetes compared with placebo (treatment-baseline lipoprotein(a) interaction P = 0.006). In the alirocumab group, a 10 mg/dL decrease in lipoprotein(a) from baseline was associated with hazard ratio 1.07 (95% CI 1.03-1.12; P = 0.0002) for incident type 2 diabetes.
Conclusions: In patients with acute coronary syndrome, baseline lipoprotein(a) concentration associated inversely with incident type 2 diabetes. Alirocumab had neutral overall effect on incident type 2 diabetes. However, treatment-related reductions in lipoprotein(a), more pronounced from high baseline levels, were associated with increased risk of incident type 2 diabetes. Whether these findings pertain to other therapies that reduce lipoprotein(a) is undetermined.
Trial registration: ClinicalTrials.gov NCT01663402.
© 2021 by the American Diabetes Association.
Figures
References
- Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol 2017;69:692–711
- Gurdasani D, Sjouke B, Tsimikas S, et al. . Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol 2012;32:3058–3065
- Langsted A, Nordestgaard BG, Kamstrup PR. Elevated lipoprotein(a) and risk of ischemic stroke. J Am Coll Cardiol 2019;74:54–66
- Laschkolnig A, Kollerits B, Lamina C, et al. . Lipoprotein (a) concentrations, apolipoprotein (a) phenotypes, and peripheral arterial disease in three independent cohorts. Cardiovasc Res 2014;103:28–36
- Sabatine MS, Giugliano RP, Keech AC, et al. .; FOURIER Steering Committee and Investigators . Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713–1722
- Schwartz GG, Steg PG, Szarek M, et al. .; ODYSSEY OUTCOMES Committees and Investigators . Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018;379:2097–2107
- Bittner VA, Szarek M, Aylward PE, et al. .; ODYSSEY OUTCOMES Committees and Investigators . Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome. J Am Coll Cardiol 2020;75:133–144
- O’Donoghue ML, Fazio S, Giugliano RP, et al. . Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation 2019;139:1483–1492
- Marston NA, Gurmu Y, Melloni GEM, et al. . The effect of PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibition on the risk of venous thromboembolism. Circulation 2020;141:1600–1607
- Schwartz GG, Steg PG, Szarek M, et al. .; ODYSSEY OUTCOMES Committees and Investigators* . Peripheral artery disease and venous thromboembolic events after acute coronary syndrome: role of lipoprotein(a) and modification by alirocumab: prespecified analysis of the ODYSSEY OUTCOMES randomized clinical trial. Circulation 2020;141:1608–1617
- Tromp TR, Stroes ESG, Hovingh GK. Gene-based therapy in lipid management: the winding road from promise to practice. Expert Opin Investig Drugs 2020;29:483–493
- Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. .; AKCEA-APO(a)-LRx Study Investigators . Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med 2020;382:244–255
- Gudbjartsson DF, Thorgeirsson G, Sulem P, et al. . Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes. J Am Coll Cardiol 2019;74:2982–2994
- Kronenberg F. Human genetics and the causal role of lipoprotein(a) for various diseases. Cardiovasc Drugs Ther 2016;30:87–100
- Ye Z, Haycock PC, Gurdasani D, et al. . The association between circulating lipoprotein(a) and type 2 diabetes: is it causal? Diabetes 2014;63:332–342
- Kaya A, Onat A, Yüksel H, Can G, Yüksel M, Ademoğlu E. Lipoprotein(a)-activated immunity, insulin resistance and new-onset diabetes. Postgrad Med 2017;129:611–618
- Mora S, Kamstrup PR, Rifai N, Nordestgaard BG, Buring JE, Ridker PM. Lipoprotein(a) and risk of type 2 diabetes. Clin Chem 2010;56:1252–1260
- Paige E, Masconi KL, Tsimikas S, et al. . Lipoprotein(a) and incident type-2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature. Cardiovasc Diabetol 2017;16:38.
- Schwartz GG, Bessac L, Berdan LG, et al. . Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J 2014;168:682–689
- Ray KK, Colhoun HM, Szarek M, et al. .; ODYSSEY OUTCOMES Committees and Investigators . Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol 2019;7:618–628
- Scharnagl H, Stojakovic T, Dieplinger B, et al. . Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays. Atherosclerosis 2019;289:206–213
- Dahlen GH. Incidence of Lp(a) Among Populations. San Diego, CA, Academic Press, 1990
- Kinpara K, Okada H, Yoneyama A, Okubo M, Murase T. Lipoprotein(a)-cholesterol: a significant component of serum cholesterol. Clin Chim Acta 2011;412:1783–1787
- Vaverková H, Karásek D, Halenka M, Cibíčková L, Kubíčková V. Inverse association of lipoprotein (a) with markers of insulin resistance in dyslipidemic subjects. Physiol Res 2017;66(Suppl. 1):S113–S120
- Kamstrup PR, Nordestgaard BG. Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study. Lancet Diabetes Endocrinol 2013;1:220–227
- Mu-Han-Ha-Li D-L-D-E, Zhai T-Y, Ling Y, Gao X. LPA kringle IV type 2 is associated with type 2 diabetes in a Chinese population with very high cardiovascular risk. J Lipid Res 2018;59:884–891
- Tolbus A, Mortensen MB, Nielsen SF, Kamstrup PR, Bojesen SE, Nordestgaard BG. Kringle IV type 2, not low lipoprotein(a), as a cause of diabetes: a novel genetic approach using SNPs associated selectively with lipoprotein(a) concentrations or with kringle IV type 2 repeats. Clin Chem 2017;63:1866–1876
- Buchmann N, Scholz M, Lill CM, et al. . Association between lipoprotein(a) level and type 2 diabetes: no evidence for a causal role of lipoprotein(a) and insulin. Acta Diabetol 2017;54:1031–1038
- Betteridge DJ, Carmena R. The diabetogenic action of statins - mechanisms and clinical implications. Nat Rev Endocrinol 2016;12:99–110
- Ference BA, Robinson JG, Brook RD, et al. . Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med 2016;375:2144–2153
- Lotta LA, Sharp SJ, Burgess S, et al. . Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: a meta-analysis. JAMA 2016;316:1383–1391
- Besseling J, Kastelein JJ, Defesche JC, Hutten BA, Hovingh GK. Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. JAMA 2015;313:1029–1036
- Lakoski SG, Lagace TA, Cohen JC, Horton JD, Hobbs HH. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab 2009;94:2537–2543
- Baass A, Dubuc G, Tremblay M, et al. . Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin Chem 2009;55:1637–1645
- Hamamura H, Adachi H, Enomoto M, et al. . Serum proprotein convertase subtilisin/kexin type 9 (PCSK9) is independently associated with insulin resistance, triglycerides, lipoprotein(a) levels but not low-density lipoprotein cholesterol levels in a general population. J Atheroscler Thromb. 4 July 2020 [Epub ahead of print]. DOI: 10.5551/jat.56390
- Ferri N, Ruscica M. Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia. Endocrine 2016;54:588–601
- Cariou B, Langhi C, Le Bras M, et al. . Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets. Nutr Metab (Lond) 2013;10:4.
- Desai NR, Giugliano RP, Wasserman SM, et al. . Association between circulating baseline proprotein convertase subtilisin kexin type 9 levels and efficacy of evolocumab. JAMA Cardiol 2017;2:556–560
- Blom DJ, Koren MJ, Roth E, et al. . Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome. Diabetes Obes Metab 2017;19:98–107
- Haynes R, Valdes-Marquez E, Hopewell JC, et al. .; HPS2-THRIVE Collaborative Group; HPS2-THRIVE Writing Committee members; HPS2-THRIVE Steering Committee members . Serious adverse effects of extended-release niacin/laropiprant: results from the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trial. Clin Ther 2019;41:1767–1777
- Grundy SM, Stone NJ, Bailey AL, et al. . 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;139:e1082–e1143
- Preiss D, Seshasai SR, Welsh P, et al. . Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011;305:2556–2564
Source: PubMed